Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Dexcom Stock Jumps As Q2 Earnings Beats Street, Raises Guidance; Analysts Bump Up Target Price


Benzinga | Aug 2, 2021 02:28PM EDT

Dexcom Stock Jumps As Q2 Earnings Beats Street, Raises Guidance; Analysts Bump Up Target Price

* Continuous glucose monitor developer Dexcom Inc (NASDAQ:DXCM) shares ticked up as second-quarter results easily topped the consensus forecast; adjusted EPS of 0.76 beat the consensus of $0.45.

* Sales increased 32% Y/Y $595.1 million, well ahead of the estimate of $551.3 million. Dexcom's biggest storyline is the expected launch of its next-generation G7 device. It has filed for the European CE mark and expects a European launch later this year, but news has been quiet regarding FDA approval and a U.S. launch.

* Outlook: Based on its strong second quarter, Dexcom said it is increasing its guidance for 2021: It expects revenue of $2.35 billion - $2.4 billion.

* Analyst Take on Earnings: Piper Sandler raised the price target to $550 from $500, with an Overweight rating unchanged.

* The new guidance range is "readily beatable," assuming that the delta variant is not too impactful, says analyst Matt O'Brien.

* Baird increased the price target to $520 from $460 and an Outperform rating.

* The analyst remains bullish, and the company has moved up a few notches on "the best growth story in MedTech" list.

* The price target at Stephens also increased to $546 from $468, with an Overweight rating as he raised his 2021 and 2022 estimates.

* Oppenheimer too beefed up the price target to $525 from $500, and Outperform rating unchanged.

* SVB Leerink also increased the price target to $500 from $485. DexCom doubled the prescribing physician base and delivered nearly 18% global sequential sales growth, nearly 2x faster than competitor Abbott's Libre, says the analyst.

* Canaccord moved the price target higher to $500 from $455 and kept a Buy rating.

* Raymond James moved the target higher to $515 from $466 and kept an Outperform, saying Dexcom "not only cleared the bar but also did so with some flair."

* Price Action: DXCM shares are up 11.80% at $509.99 during the market session on the last check Friday.

* Photo by Company







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC